CORRECT: Avacta reports progress in faridoxorubicin clinical programme
(Correcting that Avacta Group is headquartered in London). Read More
| Price | 56.50p on 03-02-2026 at 19:40:05 |
|---|---|
| Change | 7.00p 14.14% |
| Buy | 58.00p |
| Sell | 55.00p |
| Last Trade: | Unknown 53,000.00 at 56.50p |
| Day's Volume: | 4,351,998 |
| Last Close: | 56.50p |
| Open: | 49.00p |
| ISIN: | GB00BYYW9G87 |
| Day's Range | 49.00p - 56.50p |
| 52wk Range: | 27.25p - 83.20p |
| Market Capitalisation: | £247.26m |
| VWAP: | 54.12961p |
| Shares in Issue: | 437.63m |
Sector: Medicine and Biotech
Listed In: FTSE AIM All-Share,
Avacta Group (AVCT) Latest Trades |
||||
| Buy/Sell | Volume | Trade Prc | Trade Type | Trade Time |
|---|---|---|---|---|
| Unknown* | 53,000 | 56.50p | OTC Trade |
17:07:30 - 03-Feb-26 |
| Buy* | 1,685 | 57.80p | Ordinary |
16:28:26 - 03-Feb-26 |
| Buy* | 7,792 | 57.745p | Ordinary |
16:27:48 - 03-Feb-26 |
| Buy* | 2,414 | 57.745p | Ordinary |
16:27:09 - 03-Feb-26 |
| Sell* | 106 | 56.0128p | Ordinary |
16:26:31 - 03-Feb-26 |
| Buy* | 25,000 | 57.55p | Ordinary |
16:26:28 - 03-Feb-26 |
| Buy* | 674 | 57.55p | Ordinary |
16:24:25 - 03-Feb-26 |
| Buy* | 32,164 | 57.75p | Ordinary |
16:22:35 - 03-Feb-26 |
| Buy* | 500 | 57.49p | Ordinary |
16:19:00 - 03-Feb-26 |
| Sell* | 12 | 56.0128p | Ordinary |
16:16:33 - 03-Feb-26 |
Avacta Group (AVCT) Regulatory News |
||
| Date | Source | Headline |
|---|---|---|
| 21st Jan 2026 7:00 am | RNS | FDA Clearance of IND Application for AVA6103 |
| 20th Jan 2026 7:01 am | RNS | Year-end trading update |
| 20th Jan 2026 7:00 am | RNS | Appointment of Nominated Adviser & TVR |
| 18th Dec 2025 7:00 am | RNS-R | Avacta reports new AVA6103 pharmacology data |
| 17th Dec 2025 7:00 am | RNS | Faridoxorubicin Phase 1b SGC data |
| 8th Dec 2025 7:00 am | RNS | Preliminary Data in Faridoxorubicin Phase 1b Trial |
| 3rd Nov 2025 8:24 am | RNS | Completion of Placing and TVR |
| 27th Oct 2025 5:39 pm | RNS | Block Listing Six Monthly Return |
| 27th Oct 2025 7:00 am | RNS | Avacta presents preclinical data at AACR-NCI-EORTC |
| 23rd Oct 2025 5:00 pm | RNS-R | Notice of Investor Presentation |